View clinical trials related to Ischemic Stroke.Filter by:
The purpose of this study is to evaluate the antipyretic effect of bromocriptine in critically-ill patients with acute neurologic injury and fever from infectious and non-infectious etiologies.
The Bernese-European RegistrY for ischemic stroke patients treated Outside current guidelines with Neurothrombectomy Devices using the SOLITAIRE™ FR With the Intention For Thrombectomy (BEYOND-SWIFT) is a retrospective, multi-center, non-randomized observational study aims to investigate the safety and efficacy of a Medtronic market-released neurothrombectomy device (applied as initial devices used for intervention) in acute ischemic stroke patients who do not fulfill treatment eligibility according to current guidelines. Patients will be treated or were treated at the discretion of the investigator, independent of participation in this registry. Primary Analysis is the Impact of successful reperfusion on functional outcome at day 90 in patients presenting with large infarct cores (ASPECTS<6) or minor symptoms (NIHSS<8).
The study will be a multicentre, prospective, randomized, open label, blinded endpoint (PROBE) phase 3 trial (2 arm with 1:1 randomization) in ischemic stroke patients within 4.5 hours of stroke onset. Randomised patients will be stratified for site of baseline arterial occlusion into one of three groups: 1. internal carotid artery (ICA) 2. middle cerebral artery (MCA) 3. basilar artery (BA). Patients will be randomised to either bridging intravenous thrombolysis with endovascular clot retrieval (ECR), or direct endovascular clot retrieval.
Edoxaban (also referred to as Lixiana) is an anti-clotting drug, approved by Health Canada for the prevention of stroke in patients with atrial fibrillation (abnormal heart rhythm). We are doing this study to try to determine the best time to start apixaban treatment after an ischemic stroke has occurred. The purpose of the LASER study is to determine the safety of early edoxaban use after TIA/ischemic stroke in patients with atrial fibrillation using advanced MR imaging. This study will also gather information about participant general well being, mental status, and the effects of the TIA/stroke on daily living, as well as CT and MRI of the brain.
This study evaluates a program designed to help individuals transition home from inpatient rehabilitation following and ischemic stroke. Half of the participants will receive a stroke education program while the other half will receive an environmental modifications program.
Our primary aim is to investigate whether remote ischemic conditioning (RIC) as an adjunctive treatment reduce neurological impairment at 24 hours and improve long-term recovery in acute stroke patients as an adjunct to standard treatment.
Tigertriever is a CE marked mechanical revascularization device indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for IV t-PA or who fail IV t-PA therapy are candidates for treatment. The objective of the TIGER Study is to evaluate the safety and effectiveness of the Tigertriever device in restoring blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke due to a large vessel occlusion (LVO). This study is designed to support substantial equivalence to approved and marketed products such as the Solitaire or Trevo Retriever.
The purpose of this pilot study is to investigate the relationship between gut microbial composition and stroke outcome. If we can establish a relationship between gastrointestinal microbial community composition and convalescent ischemic stroke outcomes in a U.S. sample, such results would prompt further mechanistic studies, and ultimately provide a rationale for trials to determine whether modulating intestinal immune responses (e.g. via prebiotic, probiotic, or fecal transfer methods) would be beneficial.
The aims of this project are to: 1. investigate the adherence and persistence to anticoagulation (and in specific, to VKAs and NOACs) in AF patients with previous ischemic stroke; 2. identify predictors of poor adherence and persistence and 3. assess whether the SAMe-TT2R2 score predicts adherence and persistence to anticoagulation
Serum uric acid level is a commonly measured biomarker. The association between serum uric acid level and the risk of developing cardiovascular diseases has been observed in some studies, while others showed controversial results. Estimation of this association may help to predict cardiovascular outcomes and may guide new treatment strategies. The hypothesis is that increased serum uric acid level is associated with a range of cardiovascular diseases.